SCHEMBL17804227

SCHEMBL17804227

CC(=O)N(C)Cc1cccc(Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 4/20 0.40
HPGD P15428 1/20 0.40
AGTR1 P30556 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
IKBKB O14920 1/20 0.38
XPO1 O14980 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP3A4 P08684 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840494 0.81 RAB9A (0.43) ALDH1A1MAPTSMN1; SMN2POLBNPSR1
SCHEMBL5046128 0.78 PDCD1 (0.41) ALDH1A1MAPTSMN1; SMN2POLBGAA
SCHEMBL13715713 0.76 AOC3 (0.50) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL22242103 0.76 HCRTR1 (0.49)
SCHEMBL3184758 0.75 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2GAAHPGD
SCHEMBL12010833 0.74 HRH3 (0.41) ALDH1A1MAPTSMN1; SMN2POLBNPSR1
SCHEMBL17804219 0.73 SMN1; SMN2 (0.42) ALDH1A1MAPTSMN1; SMN2POLBGAA
SCHEMBL13715659 0.73 HSD17B10 (0.43) ALDH1A1MAPTPOLBGAAHPGD
SCHEMBL12012195 0.73 CYP2C19 (0.47) NPSR1IKBKBCYP2C19
SCHEMBL427048 0.72 SMN1; SMN2 (0.52) ALDH1A1MAPTSMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA ALDH1A1 4734/4885MAPT 277/4885SMN1; SMN2 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.